Vytorin vs. Leqvio

See how Vytorin and Leqvio compare on approved uses, dosing, side effects, and cost.

Key Takeaways

  • Vytorin is a once-daily pill that combines two cholesterol-lowering mechanisms, while Leqvio is an injection given just twice a year after two starter doses.

  • Vytorin has clinical trial evidence for reducing heart attacks and strokes after a cardiac event, while Leqvio's approval is based on LDL-lowering data alone.

  • Both drugs lower LDL cholesterol, but Leqvio also has approval for adolescents 12 and older with familial hypercholesterolemia.

Vytorin vs. Leqvio Drug Summary

Vytorin

Vytorin combines ezetimibe, a cholesterol absorption inhibitor, with simvastatin, a statin, in one daily tablet. It lowers LDL cholesterol, total cholesterol, and triglycerides in adults with high cholesterol, including certain inherited forms. It also has trial evidence for reducing cardiovascular events after a heart attack.

Leqvio

Leqvio (inclisiran) is a PCSK9 synthesis inhibitor given as a subcutaneous injection that lowers LDL cholesterol by silencing a liver gene involved in cholesterol regulation. It is used alongside diet changes in adults with high cholesterol and in some inherited forms starting at age 12. After two starter doses, it only needs to be injected twice a year.

Vytorin vs. Leqvio Side Effects

Vytorin

Most common
Headache (up to 5.8%)
Increased ALT (up to 3.7%)
Myalgia (up to 3.6%)

Leqvio

Most common
Injection site reaction (up to 3%)
Arthralgia (up to 3%)
Bronchitis (up to 3%)

Vytorin vs. Leqvio Dosage

Vytorin

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 10 mg/10 mg once daily At the start
Maximum dose 10 mg/80 mg once daily If needed
Dose changes 3 increases As tolerated

Leqvio

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 284 mg injection Day 1
Maximum dose 284 mg injection Same as starting
Dose changes None Fixed dose

Vytorin vs. Leqvio Indications

Vytorin

Vytorin is FDA approved to lower LDL cholesterol, total cholesterol, triglycerides, and Apo B in people with high cholesterol, and to raise HDL cholesterol. It is also approved for two rare inherited disorders: homozygous familial hypercholesterolemia and homozygous sitosterolemia.

  • Primary hyperlipidemia (high LDL, total cholesterol, triglycerides)

  • Raising HDL cholesterol

  • Homozygous familial hypercholesterolemia

  • Homozygous sitosterolemia

Leqvio

Leqvio is FDA approved as an add-on to diet and exercise to lower LDL cholesterol in adults with high cholesterol. It is also approved for heterozygous familial hypercholesterolemia in patients 12 and older, and for pediatric homozygous familial hypercholesterolemia starting at age 12.

  • Adjunct to diet and exercise for high LDL cholesterol

  • Heterozygous familial hypercholesterolemia (age 12+)

  • Pediatric homozygous familial hypercholesterolemia (age 12+)

  • Twice-yearly maintenance dosing after starter doses

Vytorin vs. Leqvio Pros and Cons

Vytorin

Vytorin is an oral option that pairs two cholesterol-lowering mechanisms in a single pill, and it is backed by outcomes data showing fewer heart attacks and strokes after a cardiac event. As a combination that includes a statin, it carries statin-specific risks like muscle pain and liver enzyme changes that Leqvio's non-statin mechanism avoids.

Pros

  • Oral tablet taken once daily, no injections

  • IMPROVE-IT trial showed fewer cardiovascular events post-heart attack

  • FDA approved for two rare inherited lipid disorders (HoFH, sitosterolemia)

  • Long-standing option, approved since 2004

Cons

  • Carries statin-related risks like myopathy and rhabdomyolysis

  • Contraindicated with strong CYP3A4 inhibitors, limiting drug combinations

  • Requires daily adherence rather than infrequent dosing

  • Not appropriate for active liver disease

Leqvio

Leqvio's twice-yearly injection schedule offers a dosing convenience that a daily pill can't match, which may help patients who struggle with adherence. Its siRNA mechanism sidesteps statin-related muscle and liver risks, but it lacks the cardiovascular outcomes data that Vytorin's statin component has generated.

Pros

  • Only two injections a year after initial starter doses

  • No statin-related muscle or liver enzyme risks

  • Approved for adolescents as young as 12 with familial hypercholesterolemia

  • Newer siRNA mechanism, distinct from statins and PCSK9 antibodies

Cons

  • No long-term cardiovascular outcomes data yet

  • Requires an in-office or self-administered injection rather than a pill

  • Risk of hypersensitivity reactions including anaphylaxis and angioedema

  • Not approved for homozygous FH in adults, only pediatric patients

Common Symptoms and Related Diseases You Can Explore

Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.